The MMRF Blog - Multiple Myeloma Research Foundation

The MMRF Blog

Cytogenetics and long-term survival of pomalidomide and low-dose dexamethasone in refractory or relapsed and refractory multiple myeloma

Dimopoulos MA, Weisel KC, Song KW, Delforge M, Karlin L, Goldschmidt H, Moreau P, Banos A, Oriol A, Garderet L, Cavo M, Ivanova V, Alegre A, Martinez-Lopez J, Chen C, Spencer A, Knop S, Bahlis NJ, Renner C, Yu X, Hong K, Sternas L, Jacques C, Zaki MH, San Miguel JF. Haematologica. 2015 Aug 6. pii: haematol.2014.117077. [Epub ahead of print] PMID: 26250580 [PubMed - as supplied by publisher] READ MORE

Posted: August 20, 2015

Monoclonal antibodies in the treatment of multiple myeloma: Current status and future perspectives

Lonial S, Durie B, Palumbo A, Miguel JS. Leukemia. 2015 Aug 12. doi: 10.1038/leu.2015.223. [Epub ahead of print] Review. PMID: 26265184 [PubMed - as supplied by publisher] READ MORE

Posted: August 20, 2015

Phase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomib

Kumar SK, LaPlant B, Roy V, Reeder CB, Lacy MQ, Gertz MA, Laumann K, Thompson MA, Witzig TE, Buadi FK, Rivera CE, Mikhael JR, Bergsagel PL, Kapoor P, Hwa L, Fonseca R, Stewart AK, Chanan-Khan A, Rajkumar SV, Dispenzieri A. Blood Cancer J. 2015 Aug 14;4:e338. doi: 10.1038/bcj.2015.60. PMID: 26275080 [PubMed - in process] READ MORE

Posted: August 20, 2015

Page 50 of 87« First...102030...4849505152...607080...Last »